The AI & Digitalisation Zone will be hosted in the exhibition area and will serve as the central hub for AI-driven drug discovery, digital R&D, and next-generation platform technologies, bringing together innovators such as Recursion, Iktos, Structural Genomics Consortium, and other leaders across AI discovery platforms, cloud infrastructure, automation, bioinformatics, digital biology, academic hubs, and strategic pharma tech partners. This interactive space will feature poster presentations, live demos, and short tech talks, alongside an AI Networking Lounge and a coffee cart to foster meaningful connections and collaboration

Experience Berlin like never before with our VR Formula One racing tour, followed by an evening of drinks, wine tasting, and invite-only exclusive dinner. Connect with peers, unwind, and enjoy the city’s sights in a relaxed, social setting.

Rafal Kaminski,
Chief Scientific Officer, Angelini Pharma 

Rafal is a neuroscience-focused innovator driving the next generation of therapies for brain and nervous system disorders. He leads the company’s scientific vision, translating cutting-edge neuroscience research into transformative medicines that address unmet patient needs, blending deep biology insight with precision drug development.

This panel explores whether neuroscience is reaching an oncology-like era of investment and innovation. Leaders will discuss shifting R&D priorities, progress in biomarkers and human-relevant models, and what is needed to translate neurological research into sustained therapeutic success. 

This closed-door panel explores what it takes to drive successful brain health innovation, from effective collaboration models and strategic partnering decisions to data-sharing and the challenges of scaling across Europe and the US, featuring perspectives from Angelini Pharma, Neurometa Therapeutics, and AstronauTX.